Recent

% | $
Quotes you view appear here for quick access.

Oculus Innovative Sciences, Inc. Message Board

  • ikabro ikabro Jan 23, 2013 8:30 PM Flag

    Microcyn Scar Management HydroGel, K103163 vs. Kelo-cote® Scar Gel for the Management of Hypertrophic or Keloid Scars

    Enrollment in its double-blind, randomized clinical study evaluating an advanced Microcyn(R) hydrogel for management of hypertrophic and keloid scars under an FDA-reviewed protocol. The data from the 40-patient trial, which includes patient treatment and eight weeks of follow-up, will be submitted to the FDA in 2013, with FDA clearance and commercialization expected later that year. Patients were recruited at four different U.S. sites: Albuquerque, NM, High Point, NC, Austin, TX and College Station, TX.

    Conditions: Hypertrophic Scar; Keloid Scar
    Interventions: Device: RD047-023; Device: Predicate Device
    Study Type: Interventional
    Sponsor: Oculus Innovative Sciences, Inc.
    Funder Type: Industry
    Study Design: Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver); Primary Purpose: Treatment
    Outcome Measures: Comparison between groups in Vancouver Scar Scale total score from Baseline to Day 112 (or early termination); Pain and itch; Adverse Events; Treatment satisfaction
    Number Enrolled: 40
    Gender: Both
    Age Group: Adult
    Start Date: August 2012
    Primary Completion Date: March 2013
    Study Completion Date:
    First Received Date: October 12, 2012
    Last Updated Date: November 30, 2012
    Last Verified Date: November 2012

    Primary Completion Date - March 2013 !

    I.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • joeleesen@ymail.com joeleesen Jan 23, 2013 8:42 PM Flag

      Well, these are the upcoming catalysts for OCLS (taken from the Vista Report)

      1. $5.1M milestone payment from More Pharma - Q32012
      2. Completion of scar reduction trial for Microcyn® - 1H2013
      3. Domestic and international expansion for Microcyn® sales -2012 and beyond
      4. Enrollment begins for acne trial for Microcyn® - 1H2013
      5. Trial design for a surgical indication for Microcyn® begins - 1H2013

      Well, the first one has been marked with a V. Third one is in the making and the rest in a month from now to 5 months from now, and of course with up-rise in income revenue, this market cap is under-valued. My estimate for the fiscal year 2013 is around 16-18M$ revenues. Surely the current market cap of 28M$ is not realistic by all means. By revenues only exc. upcoming catalysts should be traded at least two times the current FY revenues which is 36M$. Add to that the upcoming catalysts and sales and we get a much higher number.

      Add to that the latest Ruthigen shares that Oculus shareholders will receive tax-free and probably 1 or 2 other surprises in the form of new partner-ship possible in Europe and other, i believe price will be driven above 1$ in the short-run of 1-2 months but of course time will tell. Joe

      Sentiment: Strong Buy

 
OCLS
0.86+0.03(+3.05%)Jun 24 3:58 PMEDT